Ocugen, Inc. (OCGN)

Market Cap	208.12M
Revenue (ttm)	4.05M
Net Income (ttm)	-54.05M
Shares Out	292.01M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,772,256
Open	0.682
Previous Close	0.637
Day's Range	0.639 - 0.715
52-Week Range	0.515 - 2.105
Beta	3.89
Analysts	Strong Buy
Price Target	6.33 (+788.17%)
Earnings Date	Mar 5, 2025

About OCGN

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: OCGN
• Website: https://www.ocugen.com

Financial Performance

In 2024, Ocugen's revenue was $4.06 million, a decrease of -32.82% compared to the previous year's $6.04 million. Losses were -$54.05 million, -14.31% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $6.33, which is an increase of 788.17% from the latest price.

Price Target

$6.33

(788.17% upside)

Analyst Consensus: Strong Buy